NEW YORK – Nodexus, a new single-cell isolation firm, said on Thursday that it has raised $30 million in Series A financing.
RA Capital Management led the round, joined by Section 32 and previous investors.
The San Jose, California-based company said it will use the funding to develop and commercialize its microfluidics-based NX One platform for automated cell isolation and characterization.
"Flow cytometry and cell sorting are tremendously valuable techniques that can help researchers in the life science and healthcare sectors unlock new biological discoveries — but only if they have access to these tools," Nodexus founder and CEO Karthik Balakrishnan said in a statement. "The NX One system provides walk-up usable automated single-cell sorting and dispensing at unprecedented affordability to enable deployment into virtually any lab working on gene editing, cancer biology research, bioprocessing, and other quickly growing applications."
Other potential applications include drug discovery, cell line development, cell therapy, and single-cell genomics, the firm said on its website.